Aligos Therapeutics, Inc.

Nasdaq:ALGS

Biological Products, (No Diagnostic Substances)·SOUTH SAN FRANCISCO, CA

Financials

20 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	3/5/26	→
10-Q	Q3 2025	9/30/25	11/6/25	→
10-Q	Q2 2025	6/30/25	8/6/25	→
10-Q	Q1 2025	3/31/25	5/6/25	→
10-K	FY 2024	12/31/24	3/10/25	→
10-Q	Q3 2024	9/30/24	11/6/24	→
↓

Earnings Releases (8-K)

21 shown

Filed	Period
3/5/26	Q1 FY2026	→
11/6/25	Q4 FY2025	→
8/6/25	Q3 FY2025	→
5/6/25	Q2 FY2025	→
3/10/25	Q1 FY2025	→
11/6/24	Q4 FY2024	→
↓

News (8-K)

29 shown

Filed	Type	Description
2/4/26	Exec Change	Departure or Appointment of Directors or Certain Officers	→
6/26/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
2/12/25	Agreement	Entry into a Material Definitive Agreement	→
2/3/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
9/5/24	Other	Other Events	→
8/19/24	Other	Material Modification to Rights of Security Holders	→
↓

Prospectuses & Registrations

23 shown

Filed	Form	Description
3/5/26	S-8	S-8	→
8/6/25	S-8	S-8	→
4/28/25	ARS	ARS	→
4/3/25	424B3	424B3	→
3/27/25	S-3	S-3	→
3/10/25	S-8	S-8	→
↓

Filing History(321 filings)

TypeDateAccessionPeriodSize

S-8

Mar 5, 2026

0001193125-26-092647S-8

—

203.5 KB

10-K

Mar 5, 2026

0001193125-26-09261410-K

Dec 31, 2025

13.7 MB

8-K

Mar 5, 2026

0001171843-26-001340FORM 8-K

Mar 5, 2026

274.1 KB

Feb 19, 2026

0001610717-26-000055

Jan 29, 2026

14.9 KB

SCHEDULE 13G/A

Feb 17, 2026

0000902664-26-001065

—

8.8 KB

SCHEDULE 13G/A

Feb 11, 2026

0001214659-26-001502

—

9.3 KB

8-K

Feb 4, 2026

0001193125-26-0375588-K

Jan 29, 2026

134.7 KB

SCHEDULE 13G/A

Nov 14, 2025

0000902664-25-005026

—

8.8 KB

10-Q

Nov 6, 2025

0001193125-25-26820310-Q

Sep 30, 2025

8.9 MB

8-K

Nov 6, 2025

0001171843-25-007075FORM 8-K

Nov 6, 2025

267.4 KB

SCHEDULE 13G/A

Aug 14, 2025

0000902664-25-003590

—

8.6 KB

SCHEDULE 13G

Aug 13, 2025

0001214659-25-011951

—

9.2 KB

SCHEDULE 13G/A

Aug 12, 2025

0000902664-25-003496

—

12.8 KB

S-8

Aug 6, 2025

0001193125-25-174519S-8

—

207.3 KB

10-Q

Aug 6, 2025

0000950170-25-10404210-Q

Jun 30, 2025

9.3 MB

8-K

Aug 6, 2025

0001171843-25-005116FORM 8-K

Aug 6, 2025

276.7 KB

Jul 18, 2025

0001610717-25-000290

Jul 16, 2025

5.2 KB

Jul 18, 2025

0001610717-25-000289

Jul 16, 2025

5.4 KB

Jul 18, 2025

0001610717-25-000286

Jul 16, 2025

5.4 KB

Jun 26, 2025

0001610717-25-000259

Jun 25, 2025

5.2 KB

Jun 26, 2025

0001610717-25-000258

Jun 25, 2025

5.2 KB

Jun 26, 2025

0001610717-25-000257

Jun 25, 2025

5.2 KB

Jun 26, 2025

0001610717-25-000256

Jun 25, 2025

5.2 KB

Jun 26, 2025

0001610717-25-000255

Jun 25, 2025

5.2 KB

Jun 26, 2025

0001610717-25-000254

Jun 25, 2025

5.2 KB

25 filings shown

Filed	Form	Description
4/28/25	DEFA14A	DEFA14A	→
4/28/25	DEF 14A	DEF 14A	→
4/16/25	PRE 14A	PRE 14A	→
4/29/24	DEFA14A	DEFA14A	→
4/29/24	DEF 14A	DEF 14A	→
4/16/24	PRE 14A	PRE 14A	→
↓

Aligos Therapeutics, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(321 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/19/26	3	3	→
7/18/25	4	4	→
7/18/25	4	4	→
7/18/25	4	4	→
6/26/25	4	4	→
6/26/25	4	4	→
↓

Filed	Form	Description
2/17/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/11/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
11/14/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
8/14/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
8/13/25	SCHEDULE 13G	SCHEDULE 13G	→
8/12/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
↓